Infigratinib CAS# 872511-34-7 FGFR抑制剂(NVP-BGJ398)
Infigratinib is a selective, oral small-molecule inhibitor of fibroblast growth factor receptors (FGFR) 1–3, designed to block aberrant FGFR signaling implicated in tumor growth and survival. In vitro, it potently inhibits FGFR-driven cell proliferation and downstream MAPK/ERK and PI3K/AKT signaling in cancer cell lines harboring FGFR alterations. In vivo, infigratinib demonstrates robust antitumor activity in xenograft models of FGFR-dysregulated cancers, producing dose-dependent tumor regression and pathway inhibition.
📌 参考资料/链接:
Discovery of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), A Potent and Selective Inhibitor of the Fibroblast Growth Factor Receptor Family of Receptor Tyrosine KinaseBy: Guagnano, Vito; et alJournal of Medicinal Chemistry (2011), 54(20), 7066-7083
📄 详细内容
CAS No. 872511-34-7 FGFR抑制剂(NVP-BGJ398)Infigratinib synthetic routes

Discovery of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), A Potent and Selective Inhibitor of the Fibroblast Growth Factor Receptor Family of Receptor Tyrosine KinaseBy: Guagnano, Vito; et alJournal of Medicinal Chemistry (2011), 54(20), 7066-7083
产品链接: CAS No. 872511-34-7 ››